Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of dermatological science (Amsterdam)

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jdermsci.2016.12.019PMID 28069323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chromatin remodelling and autocrine TNFα are required for optimal interleukin-6 expression in activated human neutrophils

  2015cited by this paper
• Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.

  2015cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

  2014cited by this paper
• PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

  2012cited by this paper
• Serum cytokines and growth factor levels in Japanese patients with psoriasis

  2009cited by this paper
• Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis.

  2009cited by this paper
• A cytokine-mediated link between innate immunity, inflammation, and cancer.

  2007cited by this paper
• Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity

  2005cited by this paper
• Serum values of tumour necrosis factor‐&agr; and of soluble tumour necrosis factor‐R55 in melanoma patients

  2000cited by this paper

• Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer

  2026cites this paper
• The clinical characteristics, mechanism and management of immune checkpoint inhibitor-related arthritis

  2026cites this paper
• When checkpoint inhibitors break barriers: Mechanisms and challenges of irAEs of the skin, gastrointestinal tract, and lung.

  2026cites this paper
• The role of IL-6 in tumor immunity and related research progress.

  2026cites this paper
• Risk Factors and Prediction Model for Early‐Onset Immune‐Related Adverse Events in Pan‐Cancer Patients Undergoing Anti‐PD‐(L)1 Therapy: A Retrospective Study in a Tertiary‐Level Hospital

  2026cites this paper
• Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response.

  2025cites this paper
• Retrospective analysis of clinical features of pembrolizumab induced psoriasis

  2025cites this paper
• Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study

  2025cites this paper
• Ginsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6/JAK2/STAT3 pathway

  2025cites this paper
• Current status of prediction of IL-6 mediated cytochrome P450 activity modulation using in vitro data and PBPK modeling.

  2025cites this paper
• Case Report: Accelerated parathyroid adenoma progression and hypercalcemia-driven neurotoxicity following pembrolizumab-based neoadjuvant therapy in triple-negative breast cancer: a case of multisystem immune-related adverse events

  2025cites this paper
• Cationic Peptide Conjugation Enhances Intratumoral Retention and Antitumor Efficacy of Immune Checkpoint Blockade Antibodies.

  2025cites this paper
• Neuromuscular complications associated with cancer immunotherapy

  2025cites this paper
• Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice

  2024cites this paper
• Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures

  2024cites this paper
• A combination of lymphatic drug delivery of anti‐CTLA‐4 antibody and local radiotherapy for solid‐tumor treatment

  2024cites this paper
• Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma

  2024cites this paper
• Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review

  2024cites this paper
• Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors

  2024cites this paper
• Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients

  2024cites this paper
• Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors

  2024cites this paper
• Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer

  2024cites this paper
• Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

  2023cites this paper
• Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia‐Responsive Nanogels

  2023cites this paper
• Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?

  2023cites this paper
• Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature

  2023cites this paper
• CD4 T cells and toxicity from immune checkpoint blockade

  2023cites this paper
• Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.

  2023cites this paper
• Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels

  2023cites this paper
• Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

  2023cites this paper
• Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases

  2023cites this paper
• Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma

  2023cites this paper
• Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy

  2023cites this paper
• Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events

  2023cites this paper
• Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials

  2023cites this paper
• Current landscape and tailored management of immune-related adverse events

  2023cites this paper
• Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities

  2023cites this paper
• Circulating biomarkers of response to immunotherapy and immune-related adverse events

  2022cites this paper
• Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition

  2022cites this paper
• Immune-related adverse events in various organs caused by immune checkpoint inhibitors.

  2022cites this paper
• Association of anti-thyroid antibodies in checkpoint inhibitor associated thyroid immune related adverse events.

  2022cites this paper
• Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy

  2022cites this paper
• Immune Targeted Therapies for COVID-19 Infection: A Narrative Review

  2022cites this paper
• Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.

  2022cites this paper
• Advanced Materials for Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

  2022cites this paper
• Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers

  2022cites this paper
• Case Report: A Programmed Cell Death-1 Inhibitor-Related Abdominal Fibroinflammatory Reaction Affecting Multiple Organs in A Non-Small-Cell Lung Cancer Patient

  2022cites this paper
• Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

  2022cites this paper
• The role of programmed cell death ligand-1 on Langerhans cells in the regulation of psoriasis.

  2022cites this paper
• Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients

  2022cites this paper
• Contribution of skeletal muscle to cancer immunotherapy: A focus on muscle function, inflammation, and microbiota.

  2022cites this paper
• Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer

  2022cites this paper
• Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study

  2022cites this paper
• Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review

  2022cites this paper
• PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells

  2022cites this paper
• Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events

  2021cites this paper
• Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

  2021cites this paper
• Therapeutic Intervention in Skin Cancer: Future Prospects

  2021cites this paper
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

  2021cites this paper
• Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model

  2021cites this paper
• Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer

  2021cites this paper
• Therapeutic Effects of Pembrolizumab Combined with Paclitaxel and Cisplatin Chemotherapy on Advanced Non-Squamous Non-Small Cell Lung Cancer and Influencing Factors

  2021cites this paper
• Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors

  2021cites this paper
• Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.

  2021cites this paper
• Differential involvement of programmed cell death ligands in skin immune responses.

  2021cites this paper
• Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events.

  2021cites this paper
• The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors

  2021influential citation
• Single-cell analysis uncovers differential regulation of lung γδ T cell subsets by the co-inhibitory molecules, PD-1 and TIM-3

  2021cites this paper
• Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients

  2021cites this paper
• C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

  2021cites this paper
• Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors.

  2021cites this paper
• Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma

  2021cites this paper
• Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues.

  2021cites this paper
• Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment

  2021cites this paper
• The intersection of COVID-19 and cancer: signaling pathways and treatment implications

  2021cites this paper
• Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options

  2021cites this paper
• Risk factors for immune-related adverse events: what have we learned and what lies ahead?

  2021cites this paper
• Inflammatory markers in autoimmunity induced by checkpoint inhibitors

  2021cites this paper
• Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma

  2021cites this paper
• “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

  2021cites this paper
• Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.

  2021cites this paper
• Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review

  2021cites this paper
• Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities

  2020cites this paper
• Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges.

  2020cites this paper
• Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.

  2020cites this paper
• Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab.

  2020cites this paper
• Predictive biomarkers of response to immune checkpoint inhibitors in melanoma

  2020cites this paper
• Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6

  2020cites this paper
• Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist’s Perspective

  2020cites this paper
• The dark side of immunotherapy

  2020cites this paper
• Living with Metastatic Cancer: A Roadmap for Future Research

  2020cites this paper
• Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6

  2020cites this paper
• Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

  2020cites this paper
• The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

  2020cites this paper
• The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients

  2020cites this paper
• Current status and future perspectives of immunotherapy in bladder cancer treatment

  2020influential citation
• Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study

  2020cites this paper
• Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor

  2020cites this paper
• Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

  2020cites this paper
• Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.

  2020cites this paper